Traditional therapies target neurohormonal pathways, newer pharmacological agents such as sodium-glucose cotransporter 2 (SGLT2) inhibitors, soluble guanylate cyclase (sGC) stimulators, and cardiac myosin activators offer multi-targeted interventions with significant benefits in both HF with reduced ejection fraction (HFrEF ≤40%) and HFpEF [4]. Here, SLC5A2 is linked to hydrops fetalis.